Clinical trial · Interventional
Familial Pancreatic Cancer PROPHilation Program in Italy
Standardised Genetic Profiling of Subjects Belonging to the Italian Multicenter Registry of Prospective Surveillance of Subjects at Genetic Risk of Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Candidates for Hereditary Pancreatic Cancer Testing | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Saliva swab testing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Saliva testing swab
- description
- Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing
- interventionNames
- Genetic: Saliva swab testing
Primary outcomes (1)
- measure
- Presence - absence of predisposing mutations
- timeFrame
- 5 years
- description
- Prevalence of genetic mutations over the total tested
Secondary outcomes (2)
- measure
- Correlation of genetic mutations with personal oncological history
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Being enrolled on the IRFARPC registry * Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020) * Willingness to participate in saliva-swab-based genetic testing Exclusion Criteria: \- Already known genetic mutation
References
Publications (1)
- DERIVEDPaiella S, Secchettin E, Archibugi L, De Luca R, Bonifacio C, Laghi L, Lionetto G, Milanetto AC, Sereni G, Coluccio C, Lauri G, Dal Buono A, Patruno M, Gabriel G, Sassatelli R, Binda C, Bonvissuto D, Uliana V, Malleo G, Cavestro GM, Terrin M, Martino S, Pasquali C, De Pastena M, De Cobelli F, Poletti V, Venturini E, Puzzono M, Zerbi A, Arcidiacono PG, Salvia R, Falconi M, Capurso G, Carrara S. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. United European Gastroenterol J. 2026 Feb;14(1):e70187. doi: 10.1002/ueg2.70187. PMID 41691430